sd,

Celldex Presents Positive Data Demonstrating Barzolvolimab Retreatment Achieves Similar Profound Efficacy to First Exposure in Patients with Cold Urticaria (ColdU) and Symptomatic Dermographism (SD) Further Demonstrating First-in-Class and Best-in-Disease

March 01, 2026 09:45 ET  | Source: Celldex Therapeutics, Inc. - Late breaking Poster Presentation at AAAAI -- Ability to…

3 weeks ago

Fermenta Announces Granting of CEP by EDQM for VITADEE 100 SD, Enabling Accelerated Global Growth

THANE, India, July 30, 2025 /PRNewswire/ -- Fermenta Biotech Limited ("Fermenta"), a pioneer in pharmaceutical and nutritional ingredients; one of the…

8 months ago